Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Jul;100(3):115370.
doi: 10.1016/j.diagmicrobio.2021.115370. Epub 2021 Mar 13.

Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays

Katsumi Kubota  1 , Yutaro Kitagawa  1 , Masaru Matsuoka  1 , Kazuo Imai  2 , Yuta Orihara  1 , Rieko Kawamura  1 , Jun Sakai  2 , Noriomi Ishibashi  2 , Norihito Tarumoto  2 , Shinichi Takeuchi  1 , Shigefumi Maesaki  2 , Takuya Maeda  3
Affiliations
Comparative Study

Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays

Katsumi Kubota et al. Diagn Microbiol Infect Dis. 2021 Jul.

Abstract

Several automated high-throughput immunoassays for detecting anti-SARS-CoV-2 antibodies by a semi-quantitative approach have been commercialized. In this study, we describe the timeline of the antibody response in patients with RT-PCR-confirmed COVID-19. A total of 292 sequential serum samples from 33 Japanese patients were retrospectively analyzed using four test kits for SARS-CoV-2: the Abbott SARS-CoV-2 IgG assay (Abbott), Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostic), and VITROS® Anti-SARS-CoV-2 Total and IgG assays (Ortho Clinical Diagnostics). All automated immunoassays could equivalently identify positive sera collected within 2 weeks after symptom onset (99.3%-100%). In addition, the S protein-based automated immunoassay, the VITROS® Anti-SARS-CoV-2 Total assay, may play a complementary role in evaluating passive antibody therapies or vaccines against SARS-CoV-2, although further research is required.

Keywords: Antibodies; CLIA; COVID-19; ECLIA; Immunoassay; SARS-cov-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no competing interests.

Figures

Fig 1
Fig. 1
Kinetics of anti-SARS-CoV-2 antibodies in 33 patients with COVID-19. a) Signal/cutoff (S/CO) values from the Abbott SARS-CoV-2 IgG assay, b) signal sample/cutoff (COI) values from the Elecsys® anti-SARS-CoV-2 assay, c) signal/cutoff (S/C) values from the VITROS® Anti-SARS-CoV-2 Total assay, d) signal/cutoff (S/C) values from the VITROS® Anti-SARS-CoV-2 IgG assay.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Andrea P, Francesco B, Matteo P, Alessio B, Davide N, Silvia Z, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine. 2020;62 Dec. - PMC - PubMed
    1. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in boise, idaho. Clin Microbiol. 2020;58(8) doi: 10.1128/JCM.00941-20. Jul 23e00941-20Print 2020 Jul 23. - DOI - PMC - PubMed
    1. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655. doi: 10.1126/science.abc6952. Aug 7. - DOI - PMC - PubMed
    1. China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). http://kjfy.meetingchina.org/msite/news/show/cn/3337.html. Accessed July 12, 2020.
    1. Coronavirus disease (COVID-19) pandemic, WHO. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed August 9, 2020.

Substances